Passage Bio
Latest round
- Series B
Last raised
- Aug 2019
Total raised
- $226M
Investors
- 11
About Passage Bio
Established in 2018 and based in Pennsylvania, US, Passage Bio, Inc. operates as a biotechnology company that develops adeno-associated virus (AAV)-delivered therapeutics for the treatment of central nervous system diseases.
Who invested in Passage Bio
11 investors across 2 rounds
See all investors in Passage Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Passage Bio
Who invested in Passage Bio?
Passage Bio has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Passage Bio raised?
Passage Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Passage Bio last raise money?
Passage Bio's most recent round on record is a Series B, in Aug 2019.
What does Passage Bio do?
Established in 2018 and based in Pennsylvania, US, Passage Bio, Inc.
Where is Passage Bio headquartered?
Passage Bio is headquartered in Philadelphia, US.
Which VCs invest in companies like Passage Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Passage Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Passage Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.